Myriad Genetics, Inc.

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-18 EDT			5-day change	1st Jan Change
23.9 ^USD	-0.54%		+1.44%	+24.87%

06-12	Transcript : Myriad Genetics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM
06-11	Myriad Genetics, GSK Partner to Expand Access to HRD Diagnostic Testing	MT

Update to Myriad Genetics Inc.'s Equity Buyback Plan

January 31, 2012 at 04:17 pm

As of period ended on December 31, 2011, the company has repurchased 1,415,898 shares for $27.35 million.

Latest news about Myriad Genetics, Inc.

Transcript : Myriad Genetics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM	06-12
Myriad Genetics, GSK Partner to Expand Access to HRD Diagnostic Testing	06-11	MT
Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test	05-31	MT
Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test	05-31	MT
QIAGEN and Myriad Genetics Develop Distributable Homologous Recombination Deficiency Test for Global Research and Companion Diagnostics Applications	05-30	CI
Transcript : Myriad Genetics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 05:15 PM	05-14
Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating	05-13	MT
Sector Update: Health Care Stocks Softer Late Afternoon	05-08	MT
Myriad Genetics Shares Rise After Reporting Narrower Q1 Adjusted Loss, Higher Revenue	05-08	MT
Eurobio Scientific: agreement with Myriad Genetics	05-08	CF
Eurobio Scientific to Buy Gene Expression Test for Breast Cancer	05-08	MT
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q1 Revenue $202.2M, vs. Street Est of $193.3M	05-07	MT
(MYGN) MYRIAD GENETICS Sees Fiscal Year 2024 EPS Range $0.00 - $0.05	05-07	MT
(MYGN) MYRIAD GENETICS Sees Fiscal Year 2024 Revenue Range $820M - $840M	05-07	MT
Myriad Genetics to Seek Acquisitions	05-07	CI
Transcript : Myriad Genetics, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024	05-07	CI
Myriad Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Eurobio Scientific Société anonyme signed a definitive agreement to acquire EndoPredict business of Myriad Genetics, Inc for $10 million.	05-06	CI
Myriad Genetics Gets US Patent for SneakPeek Snap Device	03-20	MT
Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024	02-27
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q4 EPS $0.04, vs. Street Est of $0.01	02-27	MT
(MYGN) MYRIAD GENETICS Forecasts 2024 Revenue Range $820M - $840M	02-27	MT
Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024	02-27	CI
Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024	02-27	CI

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Myriad Genetics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

23.9 USD

Average target price

25.09 USD

Spread / Average Target

+4.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
MYRIAD GENETICS, INC.	+24.87%	2.16B
BIOMÉRIEUX	-10.54%	11.41B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-11.02%	7.53B
LANTHEUS HOLDINGS, INC.	+30.85%	5.62B
AUTOBIO DIAGNOSTICS CO., LTD.	-16.28%	3.82B
ANDON HEALTH CO., LTD.	+8.39%	2.6B
10X GENOMICS, INC.	-64.67%	2.37B
VITROLIFE AB	-9.50%	2.26B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-12.06%	1.71B
SANSURE BIOTECH INC.	-7.26%	1.43B

Diagnostic & Testing Substances

Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Update to Myriad Genetics Inc.'s Equity Buyback Plan

Latest news about Myriad Genetics, Inc.

Chart Myriad Genetics, Inc.

Company Profile

Income Statement Evolution

Ratings for Myriad Genetics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Diagnostic & Testing Substances